Lobe Sciences Appoints Mr. Yong Yao as Chief Financial Officer to Support Strategic Growth - Seite 2

"We are excited to welcome Mr. Yao to the executive team at a pivotal time," said Dr. Frederick D. Sancilio, CEO of Lobe. "His track record across biotech and financial sectors will bring valuable depth to our finance function and help strengthen our foundation as we grow."

Mr. Yao holds an MBA from McGill University, a Bachelor of Science in Biology from Nankai University, and is designated as a Fellow Chartered Management Accountant and Chartered Global Management Accountant.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS NEWS RELEASE.

About Lobe Sciences, Ltd. (CSE: LOBE), (OTCQB: LOBEF), (FWB: LOBE.F) - Lobe Sciences is a biopharmaceutical company dedicated to advancing innovative technologies for the development of urgently needed treatments for orphan and rare diseases. The company commercializes Altemia MF, a medical food formulated to address deficiencies commonly associated with sickle cell disease. Additionally, Lobe Sciences is developing S100, an orphan drug candidate aimed at treating sickle cell disease. Through Cynaptec, Lobe maintains an interest in the development of Conjugated Psilocin, targeting neurology and psychiatric conditions. The company also retains Alera Pharma, Inc. as a wholly owned subsidiary, which may be utilized for future initiatives unrelated to Conjugated Psilocin.

About Cynaptec Pharmaceuticals, Inc. - Cynaptec is a biopharmaceutical company dedicated to developing innovative therapies for neurological and psychiatric disorders. Cynaptec's initial development program is focused on the use of its proprietary Conjugated Psilocin^TM compound for treatment of the significant unmet medical needs of patients with Chronic Cluster Headache, with an additional preliminary proof-of-concept to assess potential utility for substance use disorders.

About Conjugated Psilocin^TM- Conjugated Psilocin^TM is a novel, patented, oral, stable analog of psilocin, the active metabolite of the prodrug psilocybin, designed to enhance bioavailability and therapeutic efficacy, which has been identified as having therapeutic potential in a variety of neurological conditions. Whereas conventional psilocin is an unstable compound that has been challenging for the industry to develop as a standalone pharmaceutical, Conjugated Psilocin's stability and bioavailability profile, and associated safety and efficacy signals, suggest the potential for prescription drug development in a variety of neurological and psychiatric indications.